The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic
暂无分享,去创建一个
S. Nava | V. Pasceri | A. Colombo | G. Musumeci | G. Campo | A. Rognoni | G. Patti | A. Ielasi | R. Licordari | A. Sticchi | F. Giannini | M. Borghesi | F. Tomai | Alessandro Caracciolo | A. Micari | F. Costa | S. Benenati | F. Pescetelli | G. Danzi | A. Buono | A. Scoccia | V. Cammalleri | S. Muscoli | F. Iacovelli | R. Bonmassari | I. Colaiori | F. Zilio | M. Galli | M. Pavani | R. Ruggiero | S. Albani | V. De Marzo | M. de Benedictis | F. Mancuso | M. Loffi | Domenico Scordino | Jayme Ferro | V. Regazzoni | A. Mannarini | Francesco Spione | Doronzo Baldassarre | I. Porto | J. Ferro | F. Spione | Francesco Giannini
[1] E. Mormina,et al. Suspected myocarditis in patients with COVID-19 , 2021, Medicine.
[2] H. Schünemann,et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 , 2021, Blood Advances.
[3] S. Goldhaber,et al. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19 , 2020, Journal of the American College of Cardiology.
[4] Deepak L. Bhatt,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.
[5] G. Musumeci,et al. Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE) , 2020, International Journal of Cardiology.
[6] Benjamin S. Glicksberg,et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.
[7] C. Indolfi,et al. The effects of COVID-19 on general cardiology in Italy , 2020, European heart journal.
[8] J. Thachil,et al. Coagulation abnormalities and thrombosis in patients with COVID-19 , 2020, The Lancet Haematology.
[9] M. Aepfelbacher,et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.
[10] V. Fuster,et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.
[11] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[12] Catherine Klersy,et al. Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy , 2020, The New England journal of medicine.
[13] Yutao Guo,et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.
[14] A. Falanga,et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[15] P. Ueda,et al. Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry. , 2020, European heart journal.
[16] Marco Valgimigli,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.
[17] C. Held,et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.
[18] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .
[19] J. Ware,et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.
[20] Sunil V. Rao,et al. Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.
[21] R. Califf,et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. , 2007, European heart journal.
[22] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[23] Robert M Califf,et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.
[24] W Klein,et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.
[25] Dwight E. Peake,et al. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .
[26] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.